Skip to content

    Poly Medicure

    POLYMEDGood
    Healthcare·10 Nov 2025
    Management Summary

    Poly Medicure delivered a steady Q2 performance characterized by robust domestic growth and strategic inorganic expansion in Europe. While international markets faced headwinds from Chinese competition and regulatory shifts, the company successfully closed two acquisitions to bolster its Cardiology and Orthopedic portfolios. Management is pivoting away from low-margin government business to focus on private domestic markets and high-value exports, guiding for a significant revenue ramp-up in H2 FY26.

    Highlights

    8
    • Consolidated Revenue for Q2 reached ₹444 crores, up 5.7% YoY and 10.1% QoQ.

    • Operating EBITDA margin stood at 26.8% for Q2, maintaining the higher end of the 25-27% guidance range.

    • PAT for Q2 totaled ₹92 crores, a 4.5% increase from ₹88 crores in the previous year.

    • Domestic revenue grew strongly by 17-18% in H1, with private business up 22.3% in Q2.

    • Closed two major European acquisitions: Citieffe Group (Italy) and PendraCare Group (Netherlands), adding ~₹280 crores in annual revenue.

    • Revised full-year FY26 revenue growth guidance to 15-16%, down from an initial target of ~20%.

    • Liquidity remains strong with ₹1,109 crores in cash, reducing to ~₹800 crores post-acquisition payments.

    • Renal business H1 revenue grew ~30% YoY to ₹88 crores, despite GST-related inventory realignment.

    Concerns

    2
    • US FDA Regulatory Policy Shift

    • US Tariff Uncertainty

    What Changed2

    vs Q3 FY26

    Guidance items7 → 6 (-1)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹444 Cr+5.7%YoY
    2. 02Operating EBITDA Margin26.8%
    3. 03PAT₹92 Cr+4.5%YoY
    4. 04Gross Margin69.4%+1.0%YoY
    5. 05H1 PAT₹185 Cr+14.5%YoY

    Segment breakdown

    Domestic Business
    17% Revenue Growth (Q2)22.3% Private Business Growth-14.0% Govt Business Growth32% Revenue Contribution
    International Business
    ₹300 Cr Revenue (Q2)9.1% QoQ Growth-9.6% Europe Growth (Q2)
    Renal Business
    ₹44 Cr Revenue (Q2)₹88 Cr H1 Revenue30% H1 Growth
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    H2 FY26 Revenue
    ₹1,080 - ₹1,090 crores
    High
    Revenue
    Full Year Revenue Growth
    15-16%
    Medium
    Revenue
    Renal Segment Annual Revenue
    ₹200 crores
    Medium
    Margin
    Operating EBITDA Margin
    25-27%
    High
    Capex
    Annual Capex
    > ₹250 crores
    High
    Market Share
    US Product Pipeline
    $15-$20 million
    Medium

    Risks & concerns

    6
    RiskSeverity

    US FDA Regulatory Policy Shift

    US FDA's refusal to accept Indian lab data necessitates expensive and time-consuming retesting in US labs, delaying new product launches.Management acknowledged

    high

    Chinese Competition in Europe

    Chinese companies are dumping products in Europe due to high US tariffs, impacting Polymed's European growth (9.6% YoY degrowth in Q2).Management acknowledged

    medium

    US Tariff Uncertainty

    Potential 50% tariffs in the US are described as 'completely untenable', causing customers to put new product orders on hold.Management acknowledged

    high

    GST Transition Impact

    Inventory realignment due to GST changes in September temporarily slowed Renal and domestic growth, expected to normalize in Q3.Both downplayed

    low

    Areas of Evasion(2)

    • Specific revenue/volume delta from the 20 new European products.
    • Technical details of the double-blind vs single-arm stent trials (deferred to a separate response).

    Q&A highlights

    3

    “These companies have been close to 15% EBITDA, both the companies... Only thing is, we have to just make improvements over the next quarter of the coming years, where we can increase margins to plus 20.”

    Confirms that the new acquisitions are currently margin-dilutive (15% vs Polymed's 26%+) but offers a clear turnaround plan through manufacturing synergies in India.

    asked by Amit Nigam, Invesco

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Pivot to High-Value Segments

    Polymed is aggressively shifting its focus toward Cardiology, Critical Care, and Orthopedics to drive higher margins and import substitution. In Cardiology, the company sold over 4,000 stents in H1 and is conducting a 2,000-patient clinical study for its RisoR stent to enter Tier-1 hospitals. Management noted that these segments are currently 80-90% import-dependent in India, providing a significant domestic growth runway as they localize manufacturing.

    02

    European Acquisitions to Drive Synergies

    The acquisition of Citieffe (Italy) and PendraCare (Netherlands) adds approximately ₹280 crores to the annual topline. While these entities currently operate at ~15% EBITDA margins, Polymed plans to improve this to 20%+ by leveraging its low-cost Indian manufacturing base for components. These acquisitions also provide a critical distribution footprint in Europe, helping to mitigate the 9.6% YoY degrowth seen in the region during Q2.

    03

    Domestic Market Outperformance

    The domestic business remains the primary growth engine, with private sector revenue surging 22.3% in Q2. Polymed is deliberately scaling back its government business (which degrew 14%) due to low-margin L1 tender pricing. The company is expanding its frontline presence by hiring over 100 sales associates in FY26 to capture rising local demand, guiding for 28-30% domestic growth for the full year.

    04

    Navigating US Regulatory and Tariff Headwinds

    The US market expansion faces significant friction due to a 50% tariff environment and a recent US FDA policy change rejecting Indian lab results. This has forced Polymed to restart product testing in US-based labs, delaying new approvals until mid-2026. Despite these challenges, management maintains a 3-year target of $15-$20 million for the US product pipeline, banking on a new IV catheter design expected to launch in Q4.

    05

    Capacity Expansion and Future Outlook

    Polymed is investing over ₹250 crores in capex this year, with major facilities in Mitral and Haridwar (Phase-II) expected to be operational within 12-18 months. The company is also moving its planned Jaipur facility to a 7-acre plot in YEIDA near the new Jewar airport. These investments are designed to support the target of returning to 20% organic growth in the coming years as new product pipelines in Europe and the US mature.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.